

Procalcitonin to Predict Severity of Acute Cholangitis and Need for Urgent Biliary

Decompression: Systematic Scoping Review

Krixie Silangcruz¹, Yoshito Nishimura¹, Torrey Czech¹, Nobuhiko Kimura¹, James Yess¹

¹Department of Medicine, John A. Burns School of Medicine, University of Hawai'i, Honolulu,
HI, 96813, USA

Keywords: procalcitonin, acute cholangitis, scoping review, systematic review

***Corresponding author**

Yoshito NISHIMURA, MD, PhD, MPH

1356 Lusitana St., Room 715, Honolulu, HI 96813, USA

Tel.: +1-808-203-6530; Fax: +1-808-955-2174

E-mail: yoshiton@hawaii.edu

Abstract

Background: Serum Procalcitonin (PCT) has been reported as a potential biomarker to predict the severity of acute cholangitis (AC) or the need for urgent biliary decompression. This study aimed to identify and summarize the existing research about the serum PCT and the severity of AC, and to find gaps where future studies can be targeted towards.

Methods: Following the PRISMA Extension for Scoping Reviews, MEDLINE, EMBASE, and Google Scholar were searched for all peer-reviewed articles with relevant keywords including “cholangitis” and “procalcitonin” from their inception to July 13, 2021.

Results: We identified six studies. All the studies employed case-control design and aimed to evaluate the usefulness of serum PCT to predict the severity of AC with key identified outcomes. While potential cut-off values of serum PCT for severe AC ranged from 1.8–3.1 ng/mL, studies used different severity criteria and the definition of urgent biliary decompression. No studies proposed cut-off PCT values for the need for urgent biliary decompression.

Conclusion: This scoping review identified that the current level of evidence regarding the usefulness of serum PCT in assessing the severity of AC. Further clinical research is warranted with a focus on standardized outcome measures employing prospective or experimental designs.

Introduction

Acute cholangitis (AC) is a medical emergency and systemic condition due to biliary infection and obstruction with an associated high mortality rate^{1, 2}. Before advancements in critical care and decompression of the biliary duct system, the mortality of AC was reported to be over 50%². Subsequent to 1980, the mortality rates of AC ranged from 10-30%, with multiorgan failure noted to be the cause of death³. The majority of cases of AC are due to biliary duct stones. The variety of additional etiologies underscores a wide variety of risk factors that influence mortality^{3, 4}.

Procalcitonin (PCT), a 116 amino acid peptide precursor of calcitonin, is initially thought to help identify sepsis patients and was later associated with bacterial infection⁵. However, its role in disease severity prediction remains unclear⁶, with a reported sensitivity and specificity of PCT to predict septic shock of any causes 63% and 65%, respectively⁷. Thus, the use of PCT in the diagnosis of sepsis remains a topic of contentious debate⁸.

Various studies have found PCT to be correlated with the disease severity of AC. The Tokyo Guidelines 2018 (TG18) for AC discussed the utility of PCT as a parameter for the severity assessment, stating that there was level D (very low-quality) evidence, and it might be an area of future research⁹. So far, small-scale studies have been conducted to examine the usefulness of

serum PCT values to predict the severity of AC or the need for urgent biliary decompression, using either Tokyo Guidelines 2007 (TG07) and Tokyo Guidelines 2013 (TG13)¹⁰⁻¹⁵. However, to date, no systematic reviews are available to analyze the evidence from studies across different settings and clinical outcomes to identify the trends of PCT in AC or limitations with current literature to generate recommendations in this area for future research.

The objective of this study is to scope the states of research to determine the relationship between serum PCT levels and AC disease severity, trends correlating PCT levels to different hierarchical levels of intervention as well as the need for urgent biliary decompression to identify directions for future research in this area.

Methods

Study Design

This is a systematic scoping review conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) extension for scoping reviews (PRISMA-ScR)^{16, 17}. See **Appendix 1** for PRISMA-ScR Checklist of the present study.

Search Strategy

We searched MEDLINE, EMBASE, and Google Scholar for all peer-reviewed articles and conference abstracts from inception to July 13th, 2021. No filters for study design and language were used. A manual screening for additional pertinent articles was done using the reference lists of all articles that met the eligibility criteria. The search strategy involved relevant keywords, including “cholangitis” and “procalcitonin.” The search was conducted by two authors (YN and NK) independently. See **Appendix 2** for detailed search terms.

Eligibility Criteria

The criteria for the inclusion of articles are the following:

(1) Peer-reviewed articles evaluating the relationship between serum procalcitonin levels and severity of acute cholangitis or need for biliary decompression.

(2) Randomized controlled trials (RCTs), case-control studies, cohort studies (prospective or retrospective), cross-sectional studies, and case series in adult patients

The exclusion criteria included the following:

(1) Qualitative studies, review articles, case reports, and commentaries.

(2) Conference abstracts

(3) Studies involving pediatric or obstetric patients.

Study Selection

Articles selected for full-text assessment were assessed independently by YN and NK using EndNote 20 reference management software. Articles considered eligible were then evaluated in full length with the inclusion and exclusion criteria.

Data Extraction

A standardized data collection form that followed the PRISMA and Cochrane Collaboration guidelines for systematic reviews was used to obtain the following information from each study: title, name of authors, year of publication, country of origin, study characteristics, target outcome, aims, study and comparative groups, key findings, and limitations.

Results

Search Results and Study Selection

Figure 1 shows a PRISMA flow diagram that depicts the process of identification, screening, eligibility, and inclusion or exclusion of the studies. The initial search of MEDLINE, EMBASE and Google Scholar yielded 1987 articles. 62 duplicate studies were removed, followed by the elimination of 1900 articles that were either irrelevant to our study, review articles, editorial articles, or conference abstracts with title and abstract screening. Subsequently, 25 articles

underwent a full-text review. Of these articles, 19 articles were because they were review articles, did not investigate the need for biliary drainage or cholangitis severity as an outcome, did not measure procalcitonin in the participants, or were not studies about procalcitonin and acute cholangitis. One study was also excluded because of the discrepancy between the data presented in the main text and the figures.

Description of Included Studies

A total of six studies met our eligibility criteria for the scoping review^{10-12, 14, 18, 19}. The main characteristics of the included studies are described in **Table 1**. Five were retrospective case-control studies, while one study¹² used a prospective case-control design. All the studies were from Asia (Japan, n = 4; South Korea, n = 1; China, n = 1). Sample sizes varied from 58 to 213 participants. All studies aimed to evaluate the usefulness of PCT to predict the severity of AC and were based on data from a single center.

Outcomes

Four studies also assessed blood culture positivity among participants^{11, 12, 14, 19}. The number of patients who went through urgent biliary decompression was reported in three studies^{12, 14, 19}. Of

the three studies, a study by Lee et al. and Umefune et al. reported timing of biliary decompression^{12, 14}. 4 studies assessed positivity of blood culture in patients with AC^{11, 12, 14, 19}.

Severity of Acute Cholangitis

Findings related to serum PCT levels and the severity of AC or other pertinent outcomes are summarized in **Table 2**. Except for one study¹⁰, TG13 Guidelines were used as the Severity Criteria of AC. There was a significant variation in the proportion of patients with severe AC from 7/122 (5.7%)¹⁹ to 25/110 (22.7%)¹¹. All studies reported that serum PCT levels were significantly higher in those with severe AC than those with mild or moderate AC, although the median serum PCT level differed considerably among the included articles. Area under the receiver operator characteristic (AU-ROC) of serum PCT for severe AC varied from 0.75 (95% confidence interval [CI] 0.63–0.87)¹¹ from 0.90 (95%CI 0.85–0.96)¹². Except for one study¹⁹, potential cut-off values of serum PCT for severe AC were proposed, which ranged from 1.76 ng/mL (sensitivity 84.6%, specificity 62.4%) from 3.1 ng/mL (sensitivity 80.8%, specificity 84.6%)¹⁰ using the Youden Index method, with three studies that reported similar cut-off values (Umefune et al. 2.2 ng/mL, Shinya et al. 2.33 ng/mL, Lyu et al. 2.38 ng/mL).

Procalcitonin and Urgent Biliary Decompression

Although some studies included the term “biliary drainage” or “biliary decompression”^{11, 14}, no studies proposed potential cut-off values for the need for urgent or emergent biliary decompression. The surrogate of the need for urgent or emergent biliary decompression varied considerably among the studies. Korekawa et al.¹¹ used thrombocytopenia as the surrogate and suggested that the cut-off serum PCT to predict lower platelet counts (1.3 ng/mL) might also be helpful to determine those who may need urgent biliary decompression. Shinya et al.¹¹ proposed a cut-off PCT for the presence of purulent bile juice on biliary decompression (3.2ng/mL) as the surrogate. Other studies used the severity of AC as the surrogate for the need for urgent biliary decompression. Of note, the definitions of urgent or emergent decompression were different among the articles. Korekawa et al. defined “emergent endoscopic retrograde cholangiopancreatography (ERCP)” as “the procedures done within 24 hours after admission”, while Umefune et al. defined urgent and early biliary drainage as “biliary drainage six hours and 12 hours after admission”, respectively. Other studies did not specify the term of early, urgent, or emergent biliary decompression.

Discussion

In this scoping review, we identified six primary studies related to serum PCT levels and the severity of AC or other pertinent outcomes such as blood culture positivity, progression to septic

shock, need, and timing of biliary decompression, or biliary fluid character on ERCP. All studies reported that serum PCT levels were significantly higher in those with severe AC than those with mild or moderate diseases, although the median serum PCT levels were considerably different among the included articles.

AC requires appropriate treatment in the early phase because severe AC may result in death if no early appropriate medical care is provided. Historically, TG13 proposed management bundles of AC, and TG18 re-defined the management bundles and mentioned the potential utility of serum PCT in predicting the severity of AC^{15, 20}. These guidelines classified the severity of AC into three grades; mild (grade I), moderate (grade II), and severe (grade III)²¹. In particular, TG18 severity grading criteria for AC are essential for predicting prognosis and determining a treatment strategy by identifying patients requiring early biliary drainage, although its ability to identify those who need the procedure is limited²². As noted above, there was very low-quality evidence suggesting the utility of PCT as a parameter for the severity assessment of AC when TG18 was proposed. Despite a suggestion that PCT might be a better biomarker to predict the severity of AC than white blood cell or C-reactive protein¹², unfortunately, however, there is still limited evidence regarding the point, although three years have passed since TG18.

The present study results showed that previous literature had a certain degree of consistency regarding a potential serum PCT cut-off value for severe AC (ranged from approximately 1.8 ng/mL to 3.1 ng/mL) with satisfactory AU-ROC. However, all the studies had different limitations, as described in **Table 1**. While the proposed serum PCT cut-off values for severe AC were similar, median PCT values of either moderate or severe AC differed considerably among the included studies. Of note, no studies proposed cut-off values to proceed with urgent biliary decompression, and the severity of AC was used as a surrogate of the need for the procedure. Of note, there were inconsistencies in the severity criteria used (Hamano et al. used TG07 and the others employed TG13) and the definition of either “urgent” or “emergent” decompression. For example, Umefune et al. defined urgent biliary drainage as “within 6 hours from admission”, while Lee et al. classified patients according to the timing of biliary drainage; within 24 hours, from 24 to 48 hours, or after 48 hours from a hospital visit. The differences in the guidelines used and the outcome measurements negatively affect the level of evidence.

Other limitations of the studies include that all of the currently available research were case-control studies (five retrospective and one prospective) with small sample sizes. Also, considerable heterogeneity of basic demographics among the studies needs to be noted. All the studies were conducted in Asian countries, including Japan, South Korea, and China. Further, the

etiology of AC may be different; for instance, 9.8% of patients in the study by Lee et al. had malignant biliary strictures, while Shinya et al. included only patients with choledocholithiasis. All the factors limit the generalizability of the results. Future studies may need adequate power with a prospective design and standardized outcome measurements, using the same severity criteria and the definition of urgent biliary decompression. Non-randomized controlled trial comparing the outcome of those with or without urgent biliary decompression might be necessary to establish a cut-off serum PCT value to determine the need for the procedure.

Several limitations in this study should be noted. First, due to the urgent need for evidence on this topic and limited time, we did not contact authors to clarify the details of data described in literature. Second, we only included peer-reviewed articles in this scoping review. Thus, non-peer-reviewed articles or conference abstracts, which might be useful, were excluded from the study. To the best of our knowledge, however, there has been no scoping review to investigate the utility of serum PCT to predict the severity of AC or the need for biliary decompression.

In conclusion, this scoping review identified that the current body of evidence regarding the usefulness of serum PCT in assessing the severity of AC, and potential cut-off values for the need

for urgent biliary decompression, remains scarce. In the future, further clinical research employing prospective or experimental designs is imperative to determine practical cut-off values for serum PCT for severe AC and the need for early biliary decompression.

Conflicts of Interest

The authors declare no conflicts of interest in association with the present study.

Funding

None.

Author contributions

KS conceived the study and drafted the manuscript. YN searched the literature, assessed the quality of the studies, drafted and revised the manuscript. TC performed data interpretation, drafted and revised the manuscript. NK searched the literature and revised the manuscript. JY revised the manuscript.

235

236 **References**

237 1. Lan Cheong Wah D, Christophi C, Muralidharan V. Acute cholangitis: current concepts.

238 ANZ J Surg. 2017;87(7-8):554-9.

239 2. Sulzer JK, Ocuin LM. Cholangitis: Causes, Diagnosis, and Management. Surg Clin

240 North Am. 2019;99(2):175-84.

241 3. Kimura Y, Takada T, Kawarada Y, Nimura Y, Hirata K, Sekimoto M, et al. Definitions,

242 pathophysiology, and epidemiology of acute cholangitis and cholecystitis: Tokyo Guidelines. J

243 Hepatobiliary Pancreat Surg. 2007;14(1):15-26.

244 4. Sokal A, Sauvanet A, Fantin B, de Lastours V. Acute cholangitis: Diagnosis and

245 management. J Visc Surg. 2019;156(6):515-25.

246 5. Hamade B, Huang DT. Procalcitonin: Where Are We Now? Crit Care Clin.

247 2020;36(1):23-40.

248 6. Aloisio E, Dolci A, Panteghini M. Procalcitonin: Between evidence and critical issues.

249 Clin Chim Acta. 2019;496:7-12.

250 7. Yunus I, Fasih A, Wang Y. The use of procalcitonin in the determination of severity of

251 sepsis, patient outcomes and infection characteristics. PLOS ONE. 2018;13(11):e0206527.

252 8. Wacker C, Prkno A, Brunkhorst FM, Schlattmann P. Procalcitonin as a diagnostic

253 marker for sepsis: a systematic review and meta-analysis. *Lancet Infect Dis.* 2013;13(5):426-35.

254 9. Yokoe M, Hata J, Takada T, Strasberg SM, Asbun HJ, Wakabayashi G, et al. Tokyo
 255 Guidelines 2018: diagnostic criteria and severity grading of acute cholecystitis (with videos). *J*
 256 *Hepatobiliary Pancreat Sci.* 2018;25(1):41-54.

257 10. Hamano K, Noguchi O, Matsumoto Y, Watabe T, Numata M, Yosioka A, et al.
 258 Usefulness of procalcitonin for severity assessment in patients with acute cholangitis. *Clinical*
 259 *laboratory.* 2013;59(1-2):177-83.

260 11. Shinya S, Sasaki T, Yamashita Y, Kato D, Yamashita K, Nakashima R, et al.
 261 Procalcitonin as a useful biomarker for determining the need to perform emergency biliary
 262 drainage in cases of acute cholangitis. *J Hepatobiliary Pancreat Sci.* 2014;21(10):777-85.

263 12. Umefune G, Kogure H, Hamada T, Isayama H, Ishigaki K, Takagi K, et al. Procalcitonin
 264 is a useful biomarker to predict severe acute cholangitis: a single-center prospective study.
 265 *Journal of Gastroenterology.* 2017;52(6):734-45.

266 13. Suwa Y, Matsuyama R, Goto K, Kadokura T, Sato M, Mori R, et al. IL-7 and
 267 procalcitonin are useful biomarkers in the comprehensive evaluation of the severity of acute
 268 cholangitis. *J Hepatobiliary Pancreat Sci.* 2017;24(2):81-8.

269 14. Lee YS, Cho KB, Park KS, Lee JY, Lee YJ. Procalcitonin as a Decision-Supporting
 270 Marker of Urgent Biliary Decompression in Acute Cholangitis. *Digestive Diseases and Sciences.*

271 2018;63(9):2474-9.

272 15. Yokoe M, Takada T, Strasberg SM, Solomkin JS, Mayumi T, Gomi H, et al. TG13
273 diagnostic criteria and severity grading of acute cholecystitis (with videos). J Hepatobiliary
274 Pancreat Sci. 2013;20(1):35-46.

275 16. McGowan J, Straus S, Moher D, Langlois EV, O'Brien KK, Horsley T, et al. Reporting
276 scoping reviews-PRISMA ScR extension. J Clin Epidemiol. 2020;123:177-9.

277 17. Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA
278 Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med.
279 2018;169(7):467-73.

280 18. Lyu Y, Jiang H, Wang B, Yueming X, Weibing D, Cheng Y. The role of procalcitonin in
281 patients with different severity grades of acute cholangitis. Chinese Journal of Hepatobiliary
282 Surgery. 2014;20(6):428-30.

283 19. Korekawa K, Oki M, Kumimitsu A. Evaluation of the Usefulness of Procalcitonin as a
284 Biomarker for the Diagnosis of Acute Cholangitis. Journal of Abdominal Emergency Medicine.
285 2020;40(7):809-16.

286 20. Mayumi T, Okamoto K, Takada T, Strasberg SM, Solomkin JS, Schlossberg D, et al.
287 Tokyo Guidelines 2018: management bundles for acute cholangitis and cholecystitis. J
288 Hepatobiliary Pancreat Sci. 2018;25(1):96-100.

289 21. Wada K, Takada T, Kawarada Y, Nimura Y, Miura F, Yoshida M, et al. Diagnostic
290 criteria and severity assessment of acute cholangitis: Tokyo Guidelines. J Hepatobiliary Pancreat
291 Surg. 2007;14(1):52-8.

292 22. Kiriyaama S, Kozaka K, Takada T, Strasberg SM, Pitt HA, Gabata T, et al. Tokyo
293 Guidelines 2018: diagnostic criteria and severity grading of acute cholangitis (with videos). J
294 Hepatobiliary Pancreat Sci. 2018;25(1):17-30.

295

296

297

298

299

300

301

302

303

304

305

306

Table 1. Main characteristics of the included studies in the scoping reviews

Author Year Country	Study Type	Aim	Outcome	Population	Comparative Groups	Key Findings	Limitations
Hamano et al. 2013 Japan	CC	To evaluate the usefulness of PCT for AC severity assessment	Serum PCT value	Severe AC (n = 26)	Mild (n = 39) and moderate (n = 94) AC	PCT was significantly higher in patients with severe AC than those with mild or moderate (p < 0.0001)	No cut-off for early/urgent biliary drainage. Other infections not excluded at the baseline
Korekawa et al. 2020 Japan	CC	To evaluate the usefulness of PCT to diagnose AC, and to determine a management plan	Serum PCT value Urgent biliary decompression Blood culture positivity	Severe AC (n = 7)	Mild (n = 57) and moderate (n = 58) AC	PCT was significantly higher in patients with severe AC than those with mild or moderate (p < 0.0001) Platelet was significantly lower in those with PCT of more than 1.3 ng/mL	Only seven severe AC patients were included
Lee et al. 2018 South Korea	CC	To determine the association of serum PCT with AC severity and clinical deterioration	Positive blood culture Method of biliary decompression Timing of biliary decompression	Severe AC (n = 26)	Mild (n = 39) and moderate (n = 139) AC	PCT was significantly higher in patients with severe AC than those with mild or moderate (p = 0.001) Patients who progressed to septic shock had significantly higher PCT than others (p = 0.040) No significant difference in timing of biliary decompression between groups (p = 0.341) Patients with positive blood culture (n = 65) had significantly higher	Considerable portion of patients with malignant stricture (n = 20, 9.8%) 95%CI for IQR not listed Only 6 (2.9%) patients had septic shock

							PCT than those with negative blood culture (p = 0.001)	
Lyu et al. 2014 China	CC	To evaluate the role of PCT to assess the severity of AC	Serum PCT value	Severe AC (n = 28)	Mild (n = 70) and moderate (n = 49) AC	PCT was significantly higher in patients with severe AC than those with mild or moderate (p < 0.05)	Retrospective data from a single center	
Shinya et al. 2014 Japan	CC	To evaluate the correlation of AC severity and serum PCT	Serum PCT value Blood culture positivity	Severe AC (n = 25)	Mild (n = 22) and moderate (n = 63) AC	PCT was significantly higher in patients with severe AC than those with mild AC (p < 0.001) Those with positive blood culture (n = 13) had significantly higher PCT than those with negative blood culture (n = 59; p = 0.001) In patients with mild or moderate AC, those with purulent bile juice on ERCP (n = 24) had significantly higher PCT than those with normal bile juice from the duodenal papilla (n = 48; p < 0.001)	All included patients had AC due to choledocholithiasis Blood culture was obtained only in 72 patients	
Umeforme et al. 2017 Japan	CC (prospective)	To evaluate the correlation between serum PCT on admission and severity	AC severity (TG13) The ability of PCT to predict severe AC due to	Severe AC (n = 29)	Mild (n = 108) and moderate (n = 76) AC	Patients with multiple causes of AC included (n = 107 with stent occlusion, n = 82 with choledocholithiasis, n = 24 with other) PCT was significantly higher in patients with	Small sample size to limit the robustness of secondary analyses Data from a single tertiary care center causing a bias in the characteristics of the enrolled patients	

of AC	choledocholithiasis/stenosis occlusion/positive blood culture	severe AC than those with mild AC ($p < 0.0001$) Those with positive blood culture ($n = 58$) had significantly higher PCT than those with negative blood culture ($n = 112$; $p < 0.0001$) Those with severe AC had urgent biliary drainage (within 6 hours from admission) more frequently than those with mild or moderate AC ($p = 0.0096$)
-------	--	--

Abbreviations: AC, acute cholangitis; CC, case control; ERCP, endoscopic retrograde cholangiopancreatography; IQR, interquartile range; PCT, procalcitonin; TG, Tokyo Guidelines

322

323

Table 2. Key findings related to serum procalcitonin levels in the included studies

Author Year Country	Severity Criteria Used	PCT – median (ng/mL)			Cut-off PCT for urgent biliary decompression (ng/mL)	Key Findings
		Mild AC	Moderate AC	Severe AC		
Hamano et al. 2013 Japan	TG07	0.08 (IQR; 0.04–0.18)	0.37 (IQR; 0.15–1.85)	5.56 (IQR; 3.59–25.89)	N/A	Cut-off PCT for severe AC: 3.1 ng/mL (sensitivity 80.8%, specificity 84.6%, OR 23.1 [95% CI 8.0–70.2]) AU-ROC of PCT for severe vs. mild to moderate AC = 0.86 (95% CI 0.78–0.92)
Korekawa et al. 2020 Japan	TG13	0.9 (IQR; 0.1–1.1)	9.9 (IQR; 1.2–15.9)	37.8 (IQR; 20.3–54.9)	N/A (cut-off PCT to predict those with lower platelet, who might be complicated with DIC and potential candidates for urgent biliary decompression)	AU-ROC of PCT for severe and moderate vs. mild AC = 0.89 (95% CI 0.84–0.95); no cut-off value provided Median PCT of those with positive blood culture: 12.7 ng/mL (IQR, 0.45–19.8) vs. 4.6 ng/mL (IQR, 0.2–4.9) in those with negative blood culture Cut-off PCT for positive blood culture: 1.3 ng/mL (sensitivity 67.0%, specificity 55.0%) Those with PCT > 1.3 ng/mL had significantly lower platelet than others (p < 0.0001)
Lee et al. 2018 South Korea	TG13	0.22 (IQR; 0.52)	1.35 (IQR; 4.67)	9.41 (IQR, 53.69)	N/A	Median PCT of those with positive blood culture: 3.25 ng/mL (IQR, 8.86) vs. 0.62 ng/mL (IQR, 3.78) in those with negative blood culture Median PCT of those progressed to septic shock: 9.11 ng/mL (IQR, 18.52) vs. 0.89 ng/mL (IQR, 4.34) in others Cut-off PCT for severe AC / septic shock: 1.76 ng/mL (sensitivity 84.6%, specificity 62.4%) / 3.77 ng/mL (sensitivity 80.0%, specificity 74.0%)

						AU-ROC of PCT for severe vs. mild to moderate AC = 0.778 (95%CI 0.680–0.876)
Lyu et al. 2014 China	TG13	0.166 (mean; SD ± 0.033)	0.349 (mean; SD ± 0.046)	0.759 (mean; SD ± 0.029)	N/A	Cut-off PCT for severe AC / moderate AC: 2.38 ng/mL (sensitivity 78.9%, specificity 73.7%) / 0.162 ng/mL (sensitivity 75.0%, specificity 61.1%)
Shinya et al. 2014 Japan	TG13	0.2 (IQR; 0.1–0.7)	0.7 (IQR; 0.2–2.7)	6.8 (IQR; 0.5–48.3)	N/A (cut-off PCT to predict those with purulent bile juice from the duodenal papilla was noted)	Cut-off PCT for severe AC: 2.33 ng/mL (sensitivity 64.0%, specificity 78.0%) AU-ROC of PCT for severe AC = 0.75 (95%CI 0.63–0.87) Median PCT of those with purulent bile juice: 7.9 ng/mL (IQR; 1.2–37.7) vs. 0.6 (IQR; 0.2–2.9) in those with normal bile juice Cut-off PCT for purulent bile juice: 3.2 ng/mL (sensitivity 67.0%, specificity 79.0%) AU-ROC of PCT for purulent bile juice = 0.77 (95%CI 0.64–0.89)
Umefune et al. 2017 Japan	TG13	0.45 (IQR; 0.22–1.69)	1.25 (IQR; 0.41–4.18)	19.51 (IQR; 4.41–53.36)	N/A	Cut-off PCT for severe AC: 2.2 ng/mL (sensitivity 97.0%, specificity 73.0%) AU-ROC of PCT for severe AC = 0.90 (95%CI 0.85–0.96); better than WBC or CRP Median PCT of those with positive blood culture: 4.71 ng/mL (IQR, 0.87–16.96) vs. 0.65 ng/mL (IQR, 0.25–2.26) in those with negative blood culture

Abbreviations: AC, acute cholangitis; AU-ROC, area under the receiver operator characteristic; CI, confidence interval; CRP, C-reactive protein; DIC, disseminated intravascular coagulopathy; IQR, interquartile range; OR, odds ratio; PCT, procalcitonin; SD, standard deviation; TG, Tokyo Guidelines; WBC, white blood cell

330 **Figure Legends**

331 **Figure 1. PRISMA flowchart of the search strategy**

Figure 1

